AI Article Synopsis
- Brain tumors are challenging to treat due to their ability to evade treatments by hiding behind the blood-brain barrier, making it difficult to eliminate tumorous cells without harming healthy tissue.
- Despite advancements in therapies like immunotherapy and radiotherapy, the prognosis for newly diagnosed patients remains poor, and cancer recurrence is a major issue.
- This review highlights the development of targeted radionuclide therapy techniques aimed at delivering pharmaceuticals directly to brain tumors, focusing on strategies that hone in on key cancer biomarkers for more effective treatment.
Article Abstract
Brain tumors are notoriously difficult to treat. The blood-brain barrier provides a sanctuary site where residual and metastatic cancer cells can evade most therapeutic modalities. The delicate nature of the brain further complicates the decision of eliminating as much tumorous tissue as possible while protecting healthy tissue. Despite recent advances in immunotherapy, radiotherapy and systemic treatments, prognosis of newly diagnosed patients remains dismal, and recurrence is still a universal problem. Several strategies are now under preclinical and clinical investigation to optimize delivery and maximize the cytotoxic potential of pharmaceuticals with regards to brain tumors. This review provides an overview of targeted radionuclide therapy approaches for the treatment of primary brain tumors and brain metastases, with an emphasis on biological targeting moieties that specifically target key biomarkers involved in cancer development.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723032 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics11080376 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!